Compare McCormick & Company, Incorporated (MKC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs GeneDx Holdings Corp — how do they compare? McCormick & Company, Incorporated trades at $52.93 (market cap $14.22B), while GeneDx Holdings Corp trades at $82.64 (market cap $2.44B). The key difference: McCormick & Company, Incorporated is far larger — about 5.8× GeneDx Holdings Corp's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MKC | WGS | |
|---|---|---|
Market Cap | $14.22B | $2.44B |
Sector | Consumer Staples | Technology |
52-Week High | $72.26 | $167.51 |
52-Week Low | $45.60 | $34.51 |
Enterprise Value | $18.82B | $2.48B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $53.13, up 0.32% today, with a bullish technical signal and strong profitability metrics including a 21.91% net income margin and 25.7% ROE. Recent Q2 2026 results beat expectations, driven by acquisitions and margin expansion. The pending Unilever Foods merger, expected to close in 2027, dominates news flow and offers transformative growth potential.
The outlook is positive, with a consensus price target of $59.67 implying 12% upside. Key opportunities include merger synergies and sustained dividend growth, while risks involve integration execution and soft consumer volumes. Analysts are mixed but lean bullish on valuation and strategic positioning.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
